Tiziana Plans Phase 2 Clinical Study in Moderate to Severe Covid-19 Patients with Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody
Since the anti-inflammatory effect of the nasally administered Foralumab is through the modulation of the…